Eli Lilly and Company (NYSE:LLY) Shares Up 3.3% on Earnings Beat

Key Points

• Earnings beat and stock reaction: Eli Lilly reported Q1 EPS of $8.55 versus $6.97 expected and revenue of $19.8B versus $17.82B, lifting the stock about 3.3% (intraday high ~$984) and prompting FY‑2026 EPS guidance of 35.50–37.00.
• GLP‑1 momentum and risks: Early uptake of oral GLP‑1 Foundayo (~20,000 patients) and an FDA proposal limiting compounding bolster Lilly’s pricing power and market lead, but Novo’s nationwide oral rollout and PBM pricing pressures pose competitive and margin risks amid mixed analyst views (avg. price target ~$1,219).

Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) shot up 3.3% during trading on Friday following a stronger than expected earnings report. The company traded as high as $984.45 and last traded at $965.1870. 4,312,988 shares were traded during trading, an increase of 35% from the average session volume of 3,194,880 shares. The stock had previously closed at $934.60.

The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business's quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Huge Q1 beat and upgraded guidance: Lilly reported $19.8B revenue (+56% YoY) and $8.55 EPS, handily above estimates, and raised FY‑2026 revenue and EPS guidance — a core reason the stock is rallying. Lilly's Double-Beat Widens the GLP-1 Gap
• Positive Sentiment: Foundayo early uptake — strategic product win: Foundayo (oral GLP‑1 without food/water restrictions) has already reached ~20,000 patients in early weeks; its convenience could cement Lilly’s lead in oral GLP‑1s and support longer‑term sales growth. More than 20,000 people are taking Eli Lilly's weight loss pill
• Positive Sentiment: Regulatory protection versus compounding: The FDA proposed excluding GLP‑1 actives from mass compounding lists — a move that would make cheaper compounded substitutes harder to produce and helps pricing/power for branded makers like Lilly. US FDA proposes excluding weight-loss drugs from compounding list
• Neutral Sentiment: Analyst upgrades and higher price targets: Goldman Sachs and Cantor Fitzgerald raised price targets and kept bullish ratings, supporting positive sentiment and buy interest. Cantor Fitzgerald adjusts PT on Eli Lilly
• Neutral Sentiment: Novo’s nationwide pill rollout: Novo rebranded/expanded its oral Ozempic (Rybelsus) rollout across ~70,000 U.S. pharmacies — increases competition in oral GLP‑1s and is a watch point but not an immediate earnings shock to Lilly. Novo Launches Ozempic Pills Across 70,000 US Pharmacies
• Negative Sentiment: Competition and pricing/friction risks: Analysts note Novo’s faster initial prescription ramp for its oral therapy and ongoing pricing pressure from pharmacy benefit managers (PBMs) could cap upside or compress margins over time. Eli Lilly Stock’s Path To 30% Upside
• Negative Sentiment: Small analyst forecast trims and policy friction: Some shops trimmed FY estimates modestly and industry trade groups are pushing back on Lilly’s data/340B requests — items investors watch as potential headwinds to near‑term sentiment. (See company filings and analyst notes.)

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. HSBC cut shares of Eli Lilly and Company from a "hold" rating to a "reduce" rating and cut their price objective for the company from $1,070.00 to $850.00 in a report on Tuesday, March 17th. The Goldman Sachs Group increased their target price on shares of Eli Lilly and Company from $1,260.00 to $1,283.00 and gave the stock a "buy" rating in a research note on Friday. Rothschild & Co Redburn raised their target price on Eli Lilly and Company from $875.00 to $880.00 and gave the company a "neutral" rating in a research report on Friday, April 10th. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an "overweight" rating in a research note on Thursday, February 5th. Finally, Guggenheim upped their price target on Eli Lilly and Company from $1,163.00 to $1,183.00 and gave the stock a "buy" rating in a report on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average price target of $1,218.93.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Maryland Capital Advisors Inc. acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth approximately $25,000. Osbon Capital Management LLC acquired a new position in Eli Lilly and Company in the 4th quarter valued at $25,000. Vermillion & White Wealth Management Group LLC lifted its holdings in Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock valued at $27,000 after purchasing an additional 16 shares in the last quarter. Basso Capital Management L.P. purchased a new position in Eli Lilly and Company in the 4th quarter valued at $30,000. Finally, 10Elms LLP boosted its stake in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after purchasing an additional 10 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

The firm has a market cap of $911.93 billion, a PE ratio of 42.06, a price-to-earnings-growth ratio of 1.00 and a beta of 0.51. The stock's fifty day moving average price is $947.05 and its 200-day moving average price is $984.98. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.